Urvay, Semiha ElmaciYucel, BirsenErdis, EdaTuran, Nedim2024-10-262024-10-2620161513-7368https://doi.org/10.22034/APJCP.2016.17.10.4693https://hdl.handle.net/20.500.12418/26508Aim: The objective of this study is to investigate prognostic factors affecting survival of patients undergoing concurrent or sequential chemoradiotherapy (CRT) for stage III non-small-cell lung cancer (NSCL). Methods and materials: We retrospectively reviewed the clinical records of 148 patients with advanced, inoperable stage III NSCLC, who were treated between 2007 and 2015. Results: The median survival was found to be 19 months and 3-year overall survival was 27%. Age (<65 vs >65 years, p=0.026), stage (IIIA vs IIIB, p=0.033), dose of radiotherapy (RT) (<60 vs >60 Gy, p=0.024) and treatment method (sequential chemotherapy+RT vs concurrent CRT, p=0.023) were found to be factors affecting survival in univariate analyses. Gender, histological subtype, weight loss during CRT, performance status, induction/consolidation chemotherapy and presence of comorbidities did not affect survival (p>0.050). Conclusion: Young age, stage IIIA, radiotherapy dose and concurrent chemoradiotherapy may positively affect survival in stage III NSCL cases. © 2016. All Rights Reserved.en10.22034/APJCP.2016.17.10.4693info:eu-repo/semantics/closedAccessNon-small lung cancer; prognostic factors; survivalArticle1710469746932-s2.0-85111782006Q3